rxRNA: Next Generation RNAi Compounds
Most RNAi compounds are duplexes of two strands of chemically synthesized RNA and vary significantly in efficacy, stability and specificity. The compounds can have various chemical modifications and can be of various lengths (i.e. with different number of nucleotide units). It is the combination of the length, the nucleotide sequence, and the configuration of chemical modifications that are important for effective RNAi therapeutics.
RXi uses its own version of RNAi compounds rxRNA developed by our team of world-class scientists. These proprietary rxRNA compounds provide an advanced alternative to conventional siRNAs and define the next generation of RNAi technology. rxRNA compounds are designed specifically for therapeutic use and contain many of the properties that are needed to move RNAi based drugs into the clinic. rxRNA compounds are:
- up to x 100 more active than conventional siRNA (depending on the target site)
- more resistant to nuclease degradation
- readily manufactured
- potentially more specific for the target gene
- more reliable at blocking immune side effects than conventional siRNA
rxRNA compounds comprise a new class of RNAi therapeutics. Using the various combinations of length, the nucleotide sequence, and the configuration of chemical modifications each rxRNA compound will be optimized for a particular gene target, delivery route and disease indication.
